DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020
DURECT Corporation (Nasdaq: DRRX) will announce its third quarter 2020 financial results on November 2, 2020, at 4:30 PM ET. A conference call will follow, providing key updates on their clinical programs, including DUR-928, an investigational drug targeting acute organ injury and chronic liver diseases. DUR-928 is currently in Phase 2 trials for alcoholic hepatitis and COVID-19 related injuries, and Phase 1 for nonalcoholic steatohepatitis. The company is also advancing POSIMIR, a pain relief solution.
- DUR-928 is in Phase 2 development for alcoholic hepatitis and COVID-19 liver injury.
- Potential life-saving applications for DUR-928 in chronic liver disease treatments.
- POSIMIR aims to provide extended pain relief post-surgery.
- Clinical trial outcomes for DUR-928 may not confirm earlier results.
- Regulatory approval risks for POSIMIR could limit its market presence.
- Potential delays in clinical trials for DUR-928 due to changing standards of care.
CUPERTINO, Calif., Oct. 27, 2020 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter 2020 financial results and host a conference call after the market close on Monday, November 2, 2020.
Monday, November 2 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 877-407-0784
International: 201-689-8560
Conference ID: 13712508
Webcast: http://public.viavid.com/index.php?id=142231
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DURECT's lead candidate, DUR-928 is an endogenous sulfated oxysterol and an epigenetic regulator. It represents a new class of therapeutics with a unique mechanism of action. DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways, through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival. This drug candidate is in Phase 2 development for the treatment of alcoholic hepatitis (AH) and the treatment of COVID-19 patients with acute liver or kidney injury as well as Phase 1 development for the treatment of nonalcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements in this press release regarding clinical development plans for DUR-928, including the potential use of DUR-928 to treat COVID-19 patients with liver or kidney injury, the potential use of DUR-928 to treat acute organ injuries, such as AH, and chronic liver diseases, such as NASH, the life saving potential of DUR-928, and the potential use of POSIMIR to provide pain relief after surgery are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risks that the clinical trial of DUR-928 in COVID-19 patients is delayed or stopped because of changes to the standard of care, the availability of alternative therapies, protocol changes or lack of available patients, the risk that future clinical trials of DUR-928 are not started when anticipated, take longer to conduct than anticipated, do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy or the life saving potential of DUR-928 in a statistically significant manner, the risk that the FDA will not approve POSIMIR or approve POSIMIR with a limited label, the risk that additional time and resources may be required for development, testing and regulatory approval of DUR-928 or the Company's other product candidates, potential adverse effects arising from the testing or use of our drug candidates, our potential failure to maintain our collaborative agreements with third parties and risks related to our ability to obtain capital to fund operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on August 4, 2020 under the heading "Risk Factors."
NOTE: POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928 and POSIMIR are investigational drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.
View original content:http://www.prnewswire.com/news-releases/durect-corporation-to-announce-third-quarter-2020-financial-results-and-provide-business-update-on-november-02-2020-301160360.html
SOURCE DURECT Corporation
FAQ
When will DURECT Corporation announce its third quarter 2020 financial results?
What is DUR-928 and its significance for DURECT Corporation?
What is the purpose of the upcoming conference call on November 2, 2020?
What are the risks mentioned in the DURECT Corporation press release?
How is POSIMIR related to DURECT Corporation's product pipeline?
